<DOC>
	<DOCNO>NCT02631772</DOCNO>
	<brief_summary>The predominant remaining question post-transplant treatment HCV DAA era whether ribavirin-free regimen possible whether pre-emptive treatment potential option prevent long-term damage allograft . Our aim provide answer primary question multicenter , prospective , randomize , open-label intent-to-treat phase IV study</brief_summary>
	<brief_title>LIVE-C-Free : Early Late Treatment Hepatitis C With Sofosbuvir/Ledipasvir Liver Transplant Recipients</brief_title>
	<detailed_description>This multicenter , prospective , randomize , open-label phase IV study include two subgroup : 1 . Early Cohort -- Compare ledipasvir/sofosbuvir treatment 8 week vs. 12 week patient within 90 day liver transplant 2 . Late Cohort -- Compare ledipasvir/sofosbuvir + ribavirin 12 week vs ledipasvir/sofosbuvir alone 12 week patient 90 day post-liver transplant</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Inclusion Criteria 1 . Early Cohort 1 . At least 18 year age able give inform consent 2 . History HCV genotype 1 4 3 . Normal EKG 4 . Within 90 day post orthotopic liver transplant 5 . Screening laboratory value within define threshold 6 . Creatinine Clearance least 40ml/min use Cockroft Gault equation 7 . Negative pregnancy test female subject within 48 hour prior receive study medication 8 . Use two effective contraception method female childbearing potential sexually active male unless status post bilateral tubal ligatation , bilateral oophorectomy , hysterectomy , vasectomy 2 . Late Cohort 1 . At least 18 year age able give inform consent 2 . History HCV genotype 1 4 3 . Normal EKG 4 . At least 91 day post orthotopic liver transplant 5 . Screening laboratory value within define threshold 6 . Detectable HCV RNA screen 7 . Creatinine Clearance least 40ml/min use Cockroft Gault equation 8 . Negative pregnancy test female subject within 48 hour prior receive study medication 9 . Use two effective contraception method female childbearing potential sexually active male unless status post bilateral tubal ligatation , bilateral oophorectomy , hysterectomy , vasectomy Exclusion Criteria 1 . Early Cohort 1 . Serious active medical psychiatric illness 2 . Stomach disorder could interfere absorption study drug 3 . Pregnant nursing female male pregnant female partner 4 . Recipients allograft PHS highrisk donor HIV , HBV , HCV define 2013 guideline ( See Appendix I ) , unless nucleic acid testing ( NAT ) confirm donor negative virus ' 5 . Recipients allograft donor positive HIV antibody ( Ab ) , HCV RNA PCR unknown genotype ( unless recipient demonstrate genotype 1 4 HCV replication posttransplant ) nongenotype 1 4 , HBsAg , HBV DNA PCR 6 . Coinfected HBV HIV 7 . Allergic intolerant sofosbuvir ledipasvir 8 . History exposure NS5A inhibitor 9 . History Hepatocellular Carcinoma ( HCC ) tumor burden outside Milan Criteria ( See Appendix II ) prior transplant 10 . Participated clinical study investigational drug biologic within last 30 day 11 . Combined liver/kidney transplant 12 . History organ transplant liver 13 . Patients cirrhosis 14 . Patients fibrosing cholestatic hepatitis 15 . Total bilirubin &gt; 10mg/dL 16 . ALT , AST , alkaline phosphatase ≥ 10x ULN 17 . Serum sodium &lt; 125mmol/L 18 . Current use Prohibited Interventions ( Section 5.3.2 ) unwilling discontinue use , use amiodarone within 6 month screen 2 . Late Cohort 1 . Serious active medical psychiatric illness 2 . History significant unstable cardiac disease 3 . Stomach disorder could interfere absorption study drug 4 . Pregnant nursing female male pregnant female partner 5 . Coinfected HBV HIV 6 . Recipients allograft donor infect HCV unknown genotype nongenotype 1 4 unless recipient demonstrate genotype 1 4 HCV replication posttransplant 7 . Allergic intolerant sofosbuvir , ledipasvir , ribavirin 8 . History exposure NS5A inhibitor 9 . Within 1 year transplant AND history Hepatocellular Carcinoma ( HCC ) tumor burden outside Milan Criteria ( See Appendix II ) prior transplant 10 . Participated clinical study investigational drug biologic within last 30 day 11 . Combined liver/kidney transplant 12 . History organ transplant liver 13 . Childs Turcotte Pugh ( CTP ) B C 14 . Patients fibrosing cholestatic hepatitis 15 . Platelet count ≤ 30 k/mm3 16 . Hemoglobin &lt; 10g/dL 17 . Total bilirubin &gt; 10mg/dL 18 . ALT , AST , alkaline phosphatase ≥ 10x ULN 19 . Serum sodium &lt; 125mmol/L 20 . Current use Prohibited Interventions ( Section 5.3.2 ) unwilling discontinue use , use amiodarone within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>